Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged. The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Fresenius Medical Care AG & Co. KGaA ( FMS), up 3.6%, WellPoint ( WLP), up 2.8%, Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4% and Teva Pharmaceutical Industries ( TEVA), up 1.9%. On the negative front, top decliners within the sector include Medivation ( MDVN), down 13.5%, Questcor Pharmaceuticals ( QCOR), down 7.8%, Endo Health Solutions ( ENDP), down 6.6%, Jazz Pharmaceuticals ( JAZZ), down 4.4% and Intercept Pharmaceuticals ( ICPT), down 3.5%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Covidien ( COV) is one of the companies pushing the Health Care sector higher today. As of noon trading, Covidien is up $1.03 (1.4%) to $72.37 on average volume. Thus far, 812,219 shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $71.36-$72.41 after having opened the day at $71.50 as compared to the previous trading day's close of $71.34. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $32.0 billion and is part of the health services industry. Shares are up 4.8% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts who rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.